We agree with Parsons that a niacin/lovastatin combination could be highly cost-effective, provided that patient compliance is high. Clearly, a cost-benefit analysis should be driven by long-term estimates of compliance. Unfortunately, observational data suggest that compliance rates with niacin are lower than that with other lipid-lowering drugs.1
Hamilton VH, Perreault S, Lavoie F, Grover SA. Cost-effective Treatment of Hypercholesterolemia. Arch Intern Med. 1998;158(15):1723–1724. doi:
Best of JAMA Network 2022
Customize your JAMA Network experience by selecting one or more topics from the list below.